Significance of plasma fibrinogen and malondialdehyde in the post-inflammatory period in patients with cystic fibrosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10441443" target="_blank" >RIV/00064203:_____/22:10441443 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/22:10441443 RIV/00216208:11130/22:10441443

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MIHXprp-He" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MIHXprp-He</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/BLL_2022_025" target="_blank" >10.4149/BLL_2022_025</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Significance of plasma fibrinogen and malondialdehyde in the post-inflammatory period in patients with cystic fibrosis

Popis výsledku v původním jazyce

OBJECTIVES: Evaluation of selected inflammatory parameters and serum malondialdehyde (MDA) significance in the post-inflammatory period in adult patients with cystic fibrosis. BACKGROUND: Laboratory biomarkers can be integrated into clinical practice as part of monitoring the effectiveness of treatment. METHODS: After recovery from an acute exacerbation of lung infection, selected inflammatory parameters (fibrinogen, IL-1, IL-6, SAA, hs-CRP) and serum MDA were examined in 30 adult patients with cystic fibrosis. Their correlation with FEV1, frequency and duration of subsequent hospitalizations and 6-year prognosis in terms of mortality or need for lung transplantation was evaluated. RESULTS: FEV1 negatively correlated with fibrinogen, but positively with MDA. No significant correlation with hs-CRP, IL-1, IL-6 and SAA was recorded. Plasma fibrinogen predicted the frequency and duration of subsequent hospitalizations. The 6-year prognosis was negatively associated with plasma fibrinogen whereas its association with MDA was positive. However, the prognosis of patients in the multivariate analysis was significantly associated only with FEV1. CONCLUSION: Plasma fibrinogen examined in the post-inflammatory period is a marker of lung damage in patients with cystic fibrosis and can be used to predict the prognosis. The positive correlation of serum MDA with FEV1 in the post-inflammatory period may be important to the interpretation of treatment interventions (Tab. 3, Fig. 2, Ref. 17).

Název v anglickém jazyce

Significance of plasma fibrinogen and malondialdehyde in the post-inflammatory period in patients with cystic fibrosis

Popis výsledku anglicky

OBJECTIVES: Evaluation of selected inflammatory parameters and serum malondialdehyde (MDA) significance in the post-inflammatory period in adult patients with cystic fibrosis. BACKGROUND: Laboratory biomarkers can be integrated into clinical practice as part of monitoring the effectiveness of treatment. METHODS: After recovery from an acute exacerbation of lung infection, selected inflammatory parameters (fibrinogen, IL-1, IL-6, SAA, hs-CRP) and serum MDA were examined in 30 adult patients with cystic fibrosis. Their correlation with FEV1, frequency and duration of subsequent hospitalizations and 6-year prognosis in terms of mortality or need for lung transplantation was evaluated. RESULTS: FEV1 negatively correlated with fibrinogen, but positively with MDA. No significant correlation with hs-CRP, IL-1, IL-6 and SAA was recorded. Plasma fibrinogen predicted the frequency and duration of subsequent hospitalizations. The 6-year prognosis was negatively associated with plasma fibrinogen whereas its association with MDA was positive. However, the prognosis of patients in the multivariate analysis was significantly associated only with FEV1. CONCLUSION: Plasma fibrinogen examined in the post-inflammatory period is a marker of lung damage in patients with cystic fibrosis and can be used to predict the prognosis. The positive correlation of serum MDA with FEV1 in the post-inflammatory period may be important to the interpretation of treatment interventions (Tab. 3, Fig. 2, Ref. 17).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bratislavské lekárske listy / Bratislava Medical Journal

ISSN

0006-9248

e-ISSN

—

Svazek periodika

123

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

4

Strana od-do

149-152

Kód UT WoS článku

000759059700001

EID výsledku v databázi Scopus

2-s2.0-85125275504